3Billion

3Billion EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of 3Billion (394800.KQ) as of Oct 22, 2026 is -75.11. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -60.31 — a change of 24.53% (lower).

EV/FCF

-75.11

YoY

24.53%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of 3Billion is 2025 -75.11 . EV/FCF (Enterprise Value to Free Cash Flow) of 3Billion was 2024 -60.31 . It decreases by 24.53% lower compared to the previous year.

The 3Billion EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2021
-82.83 KRW
Jan 1, 2022
-64.00 KRW
Jan 1, 2023
-84.11 KRW
Jan 1, 2024
-60.31 KRW
Jan 1, 2025
-75.11 KRW
The 3Billion EV/FCF history
YEAREV/FCFYoY
-75.11+24.53%
-60.31-28.29%
-84.11+31.42%
-64.00-22.73%
-82.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

3Billion Stock analysis

What does 3Billion do? 3Billion Inc provides genetic testing services, focusing on rare genetic disease diagnostic testing. The company develops technology to automatically read the pathogenicity of genetic variants in the genome. Its primary products are diagnostic testing services and R&D technology for genetic variants. The target customers are medical institutions and healthcare providers requiring genetic diagnostics. The company operates in the healthcare sector, specifically in genetic diagnostics and research. 3Billion Inc's revenue comes from offering diagnostic testing services to healthcare facilities and licensing its R&D technology. The firm serves medical institutions seeking accurate genetic disease diagnosis and research institutions developing genetic analysis tools. The company's services support both clinical diagnostics and scientific research in genomics. The business model centers on two main revenue streams: direct sales of genetic diagnostic services and technology licensing. Healthcare providers purchase diagnostic testing to identify rare genetic conditions, while research organizations license the automatic pathogenicity reading technology for genomic studies. The company's focus on rare genetic diseases differentiates its offerings in the medical diagnostics market. 3Billion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 3Billion stock

EV/FCF (Enterprise Value to Free Cash Flow) of 3Billion is -75.11 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of 3Billion changed from -60.31 to -75.11, representing a 24.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) 3Billion since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s 3Billion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — 3Billion

All Key Metrics — 3Billion